Back to results
US 12,590,166 B2Granted
CD20 binding molecules and uses thereof
AssigneesLegend Biotech Ireland Limited, Legend Biotech USA Inc.
InventorsXiaohu Fan, Zhe Zhou, Qiuchuan Zhuang, Xu Fang, Hongbo Pan, Min Wei, Jianrui Zhu
Life of this patent
Estimating the term…
Abstract
The present disclosure provides single domain antibodies that bind to CD20, and chimeric antigen receptors comprising same. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating a disease or disorder are also provided.
Claims20
An anti-CD20 single domain antibody (sdAb) comprising:
- (i) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1 or 195;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 2;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 3;
- (ii) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 5;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6;
- (iii) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1 or 195;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 7;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 8;
- (iv) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 9;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 10;
- (v) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 11 or 196;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 12;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 8;
- (vi) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 13;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 9;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 10;
- (vii) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 14 or 197;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 15;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (viii) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 17;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 18;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 19;
- (ix) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 20 or 197;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 21;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (x) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 23;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 19;
- (xi) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 24 or 198;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 25;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 26;
- (xii) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 27;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 28;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 29;
- (xiii) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 14 or 197;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 30;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (xiv) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 17;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 31;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 19;
- (xv) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1 or 195;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 32;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 3;
- (xvi) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 33;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6;
- (xvii) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 20 or 197;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 34;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (xviii) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 35;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 19;
- (xix) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 20 or 197;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 36;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (xx) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 20 or 197;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 37;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (xxi) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 20 or 197;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 38;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (xxii) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 33;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 39;
- (xxiii) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 33;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 40;
- (xxiv) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 165 or 199;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 166;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 167;
- (xxv) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 168;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 169;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 170;
- (xxvi) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 171 or 200;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 172;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 173;
- (xxvii) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 174;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 175;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 176;
- (xxviii) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 177 or 197;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 178;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 179;
- or
- (xxix) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 180;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 181;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 182.
172 more elements
An anti-CD20 single domain antibody (sdAb) comprising:
- (i) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 41;
- (ii) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 42;
- (iii) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 43;
- (iv) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 44;
- (v) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 45;
- (vi) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 46;
- (vii) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 47;
- (viii) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 48;
- (ix) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 49;
- (x) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 50;
- (xi) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 51;
- (xii) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 52;
- (xiii) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 53;
- (xiv) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 54;
- (xv) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 55;
- (xvi) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 56;
- (xvii) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 57;
- (xviii) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 58;
- (xix) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 59;
- (xx) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 60;
- (xxi) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 61;
- (xxii) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 62;
- (xxiii) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 63;
- (xxiv) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 183;
- (xxv) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 184;
- or
- (xxvi) a CDR1, a CDR2, and a CDR3 having the amino acid sequences of the CDR1, CDR2, and CDR3, respectively, as set forth in SEQ ID NO:
- 185.
50 more elements
A chimeric antigen receptor (CAR), comprising (i) an amino acid sequence selected from the group consisting of SEQ ID NO:
- 81, SEQ ID NO:
- 82, SEQ ID NO:
- 83, SEQ ID NO:
- 84, SEQ ID NO:
- 85, SEQ ID NO:
- 86, SEQ ID NO:
- 87, SEQ ID NO:
- 88, SEQ ID NO:
- 89, SEQ ID NO:
- 90, SEQ ID NO:
- 91, SEQ ID NO:
- 92, SEQ ID NO:
- 93, SEQ ID NO:
- 94, SEQ ID NO:
- 95, SEQ ID NO:
- 96, SEQ ID NO:
- 97, SEQ ID NO:
- 98, SEQ ID NO:
- 99, SEQ ID NO:
- 100, SEQ ID NO:
- 101, SEQ ID NO:
- 102, SEQ ID NO:
- 103, SEQ ID NO:
- 104, SEQ ID NO:
- 105, SEQ ID NO:
- 106, SEQ ID NO:
- 189, SEQ ID NO:
- 190, and SEQ ID NO:
- 191;
- or (ii) an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more sequence identity with the sequence of SEQ ID NO:
- 81, SEQ ID NO:
- 82, SEQ ID NO:
- 83, SEQ ID NO:
- 84, SEQ ID NO:
- 85, SEQ ID NO:
- 86, SEQ ID NO:
- 87, SEQ ID NO:
- 88, SEQ ID NO:
- 89, SEQ ID NO:
- 90, SEQ ID NO:
- 91, SEQ ID NO:
- 92, SEQ ID NO:
- 93, SEQ ID NO:
- 94, SEQ ID NO:
- 95, SEQ ID NO:
- 96, SEQ ID NO:
- 97, SEQ ID NO:
- 98, SEQ ID NO:
- 99, SEQ ID NO:
- 100, SEQ ID NO:
- 101, SEQ ID NO:
- 102, SEQ ID NO:
- 103, SEQ ID NO:
- 104, SEQ ID NO:
- 105, SEQ ID NO:
- 106, SEQ ID NO:
- 189, SEQ ID NO:
- 190, or SEQ ID NO:
- 191.
56 more elements
Dependencies are inferred from the claim text.